Payment overview · 2025
General Payments
$623.02
36 reported records · 12 companies
Healthcare provider profile · identity verified
Brandon A. West, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · POCATELLO, ID · NPI 1750490660
Verified facts
What the public records show
CMS Open Payments records show Brandon A. West, D.O. received $623.02 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Armour Thyroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $151.96 | 24.4% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.28 | 16.6% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $74.83 | 12.0% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.62 | 10.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $62.19 | 10.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.35 | 7.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.48 | 5.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.18 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.40 | 2.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.77 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.00 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.96 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $623.02 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $91.32 | 6 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $74.83 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.36 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $63.62 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $62.19 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $60.64 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $49.35 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.68 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.81 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 390 | 107 |
| Losartan Potassium | Losartan Potassium | 311 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 174 | 45 |
| Metformin Hcl | Metformin Hcl | 160 | 46 |
| Sertraline Hcl | Sertraline Hcl | 155 | 41 |
| Omeprazole | Omeprazole | 153 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 37 |
| Gabapentin | Gabapentin | 129 | 32 |
| Simvastatin | Simvastatin | 126 | 34 |
| Lisinopril | Lisinopril | 106 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 18 |
| Famotidine | Famotidine | 99 | 26 |
| Trazodone Hcl | Trazodone Hcl | 95 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 23 |
| Ozempic | Semaglutide | 87 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | 19 |
| Carvedilol | Carvedilol | 71 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 15 |
| Mounjaro | Tirzepatide | 68 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 22 |
| Farxiga | Dapagliflozin Propanediol | 64 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 16 |
| Estradiol | Estradiol | 55 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 54 | 12 |
| Metformin Hcl Er | Metformin Hcl | 52 | 16 |
| Allopurinol | Allopurinol | 49 | 13 |
| Tramadol Hcl | Tramadol Hcl | 46 | 16 |
| Furosemide | Furosemide | 45 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 14 |
| Jardiance | Empagliflozin | 42 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 11 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Potassium Chloride | Potassium Chloride | 39 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 12 |
| Bupropion Xl | Bupropion Hcl | 38 | 11 |
| Meloxicam | Meloxicam | 37 | 14 |
| Atenolol | Atenolol | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Lorazepam | Lorazepam | 26 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 17 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $623.02 · 36 records | ABBVIE INC. | AIRSUPRA, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FANAPT, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, Ozempic, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error